Pilot Observational Study of an Integrative Cure Stay Program
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorUniversity Hospital, Basel, Switzerland
About this trial
This pilot observational study evaluates the feasibility and acceptability of conducting a prospective study alongside the individualized integrative oncology cure stay program "Via Shalva" for breast and gynecological cancer survivors. The study further explores preliminary changes in patient-reported outcomes, physiological measures, and biological markers before and after the retreat and compared with a matched control group.
Eligibility criteria
Qualifiers
Breast and gynecological cancer (including but not limited to ovarian, endometrial, cervical, vulvar and vaginal cancer) survivors, including recurrent disease
Completed primary treatment (operation +/- radiation +/- chemotherapy)
Age ≥ 18 years
Ongoing or planned maintenance treatment scheduled for > 3 months during study period is allowed (e.g. antihormonal therapy, Anti-Her2-antibodies, CDK4/6-inhibitors, Anti-VEGF-inhibitor, PARP-inhibitor, immune-checkpoint inhibitors etc.)
Disqualifiers
Language or cognitive deficits (including impaired consciousness) that are incompatible with the participation in the study
Severe physical or psychiatric comorbidity that prevents a patient from participating in the study
Patients incapable of giving consent
Trial design
Treatments tested in this trial
- Integrative Cure Stay
- Matched Control Group
Treatment groups
30 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov